RxDoctor Payments Data

Kevin Palka, MD

Hematology & Oncology · Hannibal, MONPI 1689721482

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $26,225 of the $39,895 with a category attached, or 65.7%. 42 manufacturers reported payments, led by Merck at 51.8% of the total. Reporting peaked in 2019 at $32,155 and has fallen 97.0% since, to $955 in 2025. Among hematology & oncology clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$39,895in general payments, 2019–2025

Across 263 payments — averaging $151.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$21K
  • Genentech USA, Inc.$12K
  • AbbVie$3K
  • Novartis$649
  • Johnson & Johnson$561
  • Pfizer$339
  • plus $3K from 36 others

What the payments were for

  • Consulting fees$2,2006%
  • Speaking & faculty fees$26,22566%
  • Travel & lodging$5,25813%
  • Food & beverage$5,49314%
  • Education$7192%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$39,895 in reported general payments places this provider in the 90th percentile of 211 hematology & oncology providers in Missouri.

See all hematology & oncology providers in Missouri

Medicare billing

Part B allowed, 2024
$52,672
Medicare patients
159
Services billed
465

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BrukinsaZanubrutinib26$390,232
XtandiEnzalutamide14$203,025
VenclextaVenetoclax13$196,322
BraftoviEncorafenib11$178,483
Kisqali Femara Co-PackRibociclib Succinate/Letrozole12$168,302
ErleadaApalutamide11$164,188
Abiraterone Acetate29$138,611
Anastrozole100$1,077
Tamoxifen Citrate47$931
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen19$826
Morphine Sulfate ErMorphine Sulfate17$705
Ondansetron OdtOndansetron28$661
Hydroxyurea13$661
Potassium Chloride37$619
Prochlorperazine Maleate26$609

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi$39$203,02514 claims
AbbVieVenclexta$2,795$196,32213 claims
Array Biopharma IncBraftovi$49$178,48311 claims
Johnson & JohnsonErleada$561$164,18811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 211 hematology & oncology providers in Missouri.

Other hematology & oncology in Hannibal

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →